Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

Charles Dumontet

INSERM U590

Laboratoire de Cytologie Analytique

Faculte de Medecine Rockefeller

France

[email]@chu-lyon.fr

Name/email consistency: high

[Claim this account]

Affiliations

Charles Dumontet, INSERM U590, Laboratoire de Cytologie Analytique, Faculte de Medecine Rockefeller, France. 2011
LCMT, Hospices Civils de Lyon, France. 2010
INSERM 590, Faculté Rockefeller, 8 Avenue Rockefeller, France. 2010
Unité Institut National de la Sante et de la Recherche Medicale 590, Laboratoire de Cytologie Analytique, Faculté de Médecine Rockefeller, 8 Avenue Rockefeller, France. 2009
Service d'Hématologie, Centre Hospitalier Lyon Sud, 69495 Pierre Bénite Cedex, France. 2000 - 2006
Services d'Hématologie Pierre Bénite, Lille, France. 2001 - 2003

References

Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Dalle, S., Reslan, L., Besseyre de Horts, T., Herveau, S., Herting, F., Plesa, A., Friess, T., Umana, P., Klein, C., Dumontet, C. Mol. Cancer Ther. (2011) [Pubmed]
Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan. Dumontet, C., Landi, S., Reiman, T., Perry, T., Plesa, A., Bellini, I., Barale, R., Pilarski, L.M., Troncy, J., Tavtigian, S., Gemignani, F. Bone Marrow Transplant. (2010) [Pubmed]
BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy. Dumontet, C., Krajewska, M., Treilleux, I., Mackey, J.R., Martin, M., Rupin, M., Lafanechère, L., Reed, J.C. Clin. Cancer Res. (2010) [Pubmed]
Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies. Dumontet, C., Jordan, M.A., Lee, F.F. Mol. Cancer Ther. (2009) [Pubmed]
A phase II trial of miltefosine in patients with cutaneous T-cell lymphoma. Dumontet, C., Thomas, L., Bérard, F., Gimonet, J.F., Coiffier, B. Bull. Cancer (2006) [Pubmed]
Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Dumontet, C., Isaac, S., Souquet, P.J., Bejui-Thivolet, F., Pacheco, Y., Peloux, N., Frankfurter, A., Luduena, R., Perol, M. Bull. Cancer (2005) [Pubmed]
Clinical and pharmacokinetic phase II study of fotemustine in refractory and relapsing multiple myeloma patients. Dumontet, C., Jaubert, J., Sebban, C., Bouafia, F., Ardiet, C., Tranchand, B., Berger, E., Lucas, C., Guyotat, D., Coiffier, B. Ann. Oncol. (2003) [Pubmed]
Factors predictive of early death in patients receiving high-dose CHOP (ACVB regimen) for aggressive non-Hodgkin's lymphoma: a GELA study. Dumontet, C., Mounier, N., Munck, J.N., Bosly, A., Morschauser, F., Simon, D., Marit, G., Casasnovas, O., Reman, O., Molina, T., Reyes, F., Coiffier, B. Br. J. Haematol. (2002) [Pubmed]
The superoxide dismutase content in erythrocytes predicts short-term toxicity of high-dose cyclophosphamide. Dumontet, C., Drai, J., Thieblemont, C., Hequet, O., Espinouse, D., Bouafia, F., Salles, G., Coiffier, B. Br. J. Haematol. (2001) [Pubmed]
Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. Dumontet, C., Morschhauser, F., Solal-Celigny, P., Bouafia, F., Bourgeois, E., Thieblemont, C., Leleu, X., Hequet, O., Salles, G., Coiffier, B. Br. J. Haematol. (2001) [Pubmed]
Mechanisms of action and resistance to tubulin-binding agents. Dumontet, C. Expert. Opin. Investig. Drugs (2000) [Pubmed]

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.